Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company focused on innovative eye therapy delivery, will have its CEO George Lasezkay participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference. This event is scheduled for April 19, 2023, at 1:30 p.m. ET. A live and archived webcast will be available on Clearside's website for three months in the Investors section. Clearside specializes in delivering treatments to the back of the eye through the suprachoroidal space (SCS®) using its proprietary SCS Microinjector®. Its first product, XIPERE®, is already available in the U.S. for ocular conditions. The company partners strategically to leverage other ophthalmic innovations.

ALPHARETTA, Ga., April 12, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 22^nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023, at 1:30 p.m. ET.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Source: Clearside Biomedical, Inc.

FAQ

What is Clearside Biomedical's participation in the 22nd Annual Needham Virtual Healthcare Conference?

Clearside Biomedical's CEO, George Lasezkay, will participate in a Fireside Chat at the conference on April 19, 2023, at 1:30 p.m. ET.

How can I access the webcast of Clearside Biomedical's conference appearance?

The live and archived webcast for Clearside Biomedical's conference appearance can be accessed on their website under the Investors section.

What is the focus of Clearside Biomedical's therapies?

Clearside Biomedical focuses on delivering therapies to the back of the eye through the suprachoroidal space (SCS®) using its innovative SCS Microinjector®.

What product has Clearside Biomedical launched in the U.S.?

Clearside Biomedical's first product launched in the U.S. is XIPERE®, an injectable suspension for suprachoroidal use.

When will the archived webcast of Clearside Biomedical's presentation be available?

The archived webcast of Clearside Biomedical's presentation will be available for three months after the event.